{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:02:40Z","timestamp":1789578160379,"version":"build-2803163510"},"reference-count":71,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Oral absorption remains challenging for peptides, proteins, and other drug substances with limited stability or permeability. Sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC), also known as salcaprozate sodium, is an oral permeation enhancer used in approved drug products. This review summarizes the physicochemical properties and mechanisms of action of SNAC and evaluates its clinical and emerging preclinical applications. A structured literature search was conducted in PubMed and Scopus, supplemented as needed with ClinicalTrials.gov and regulatory documents. The search covered 2015\u20132026, with earlier key publications included where necessary for historical context. After screening, 71 sources were included in the narrative synthesis. The review examines the proposed mechanisms of SNAC-mediated permeation enhancement, including local pH modulation, membrane-mediated effects, peptide self-association, and context-dependent effects on epithelial permeability. Clinical evidence is summarized for oral semaglutide, cyanocobalamin, unfractionated heparin, ibandronate, and investigational peptide products. Emerging applications beyond metabolic diseases are discussed together with formulation strategies and safety considerations. Recent preclinical findings suggesting changes in gut microbiota and inflammatory markers are critically evaluated in the context of the available clinical safety experience, while their relevance to humans remains unconfirmed. Overall, SNAC reliably enhances permeation in vitro and in vivo, yet the resulting oral bioavailability remains low and variable and is strongly dependent on payload, formulation, and gastrointestinal conditions. Long-term safety and the clinical relevance of recent preclinical microbiome findings remain important areas for future investigation.<\/jats:p>","DOI":"10.3390\/pharmaceutics18091171","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:07:29Z","timestamp":1789574849000},"page":"1171","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Salcaprozate Sodium as a Permeation Enhancer\u2014Mechanism, Applications and Unresolved Questions"],"prefix":"10.3390","volume":"18","author":[{"given":"Boris","family":"Dinkov","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy, Medical University, 5800 Pleven, Bulgaria"},{"name":"Clinic of Endocrinology and Metabolic Diseases, University Hospital \u201cDr. Georgi Stranski\u201d, 5800 Pleven, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8458-856X","authenticated-orcid":false,"given":"Nikolinka","family":"Koleva","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy, Medical University, 5800 Pleven, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-1980","authenticated-orcid":false,"given":"Galya","family":"Stavreva","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy, Medical University, 5800 Pleven, Bulgaria"},{"name":"Center of Competence in Personalized Medicine, 3D and Telemedicine, Robotic and Minimally Invasive Surgery \u201cLeonardo da Vinci\u201d, Medical University, 5800 Pleven, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.apsb.2021.04.001","article-title":"Oral Delivery of Proteins and Peptides: Challenges, Status Quo and Future Perspectives","volume":"11","author":"Zhu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Twarog, C., Fattah, S., Heade, J., Maher, S., Fattal, E., and Brayden, D.J. (2019). Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10). Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11020078"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.addr.2016.06.005","article-title":"Intestinal Permeation Enhancers for Oral Peptide Delivery","volume":"106","author":"Maher","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Asano, D., Takakusa, H., and Nakai, D. (2023). Oral Absorption of Middle-to-Large Molecules and Its Improvement, with a Focus on New Modality Drugs. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16010047"},{"key":"ref_5","first-page":"11","article-title":"Recent Progress in the Oral Delivery of Therapeutic Peptides and Proteins: Overview of Pharmaceutical Strategies to Overcome Absorption Hurdles","volume":"14","author":"Mehrotra","year":"2024","journal-title":"Adv. Pharm. Bull."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kim, J.C., Park, E.J., and Na, D.H. (2022). Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals. Pharmaceuticals, 15.","DOI":"10.3390\/ph15121585"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s11095-022-03459-9","article-title":"SNAC for Enhanced Oral Bioavailability: An Updated Review","volume":"40","author":"Kommineni","year":"2023","journal-title":"Pharm. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1021\/jm00021a015","article-title":"N-Acylated .Alpha.-Amino Acids as Novel Oral Delivery Agents for Proteins","volume":"38","author":"Santiago","year":"1995","journal-title":"J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/1091581809337737","article-title":"Subchronic Oral Toxicity of Salcaprozate Sodium (SNAC) in Sprague-Dawley and Wistar Rats","volume":"28","author":"Riley","year":"2009","journal-title":"Int. J. Toxicol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13346-021-01000-w","article-title":"Development and Approval of Rybelsus (Oral Semaglutide): Ushering in a New Era in Peptide Delivery","volume":"12","author":"Lewis","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"eaar7047","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular Stomach Absorption of a Derivatized Glucagon-like Peptide-1 Receptor Agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"105509","DOI":"10.1016\/j.ejps.2020.105509","article-title":"Salcaprozate Sodium (SNAC) Enhances Permeability of Octreotide across Isolated Rat and Human Intestinal Epithelial Mucosae in Ussing Chambers","volume":"154","author":"Fattah","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1208\/s12249-026-03424-4","article-title":"Influence of pH, Buffering Capacity, Ionic Strength, Bile Salts, and Model Drugs on Micellization Behaviour of Salcaprozate Sodium in Physiological Range pH Buffers","volume":"27","author":"Akbar","year":"2026","journal-title":"AAPS PharmSciTech"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2020.04.023","article-title":"A Head-to-Head Caco-2 Assay Comparison of the Mechanisms of Action of the Intestinal Permeation Enhancers: SNAC and Sodium Caprate (C10)","volume":"152","author":"Twarog","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"105685","DOI":"10.1016\/j.ejps.2020.105685","article-title":"Comparison of the Effects of the Intestinal Permeation Enhancers, SNAC and Sodium Caprate (C10): Isolated Rat Intestinal Mucosae and Sacs","volume":"158","author":"Twarog","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/acs.molpharmaceut.4c01061","article-title":"Molecular Investigation of SNAC as an Oral Peptide Permeation Enhancer in Lipid Membranes via Solid-State NMR","volume":"22","author":"Ling","year":"2025","journal-title":"Mol. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9512","DOI":"10.1038\/s41467-025-64891-0","article-title":"Permeation Enhancer-Induced Membrane Defects Assist the Oral Absorption of Peptide Drugs","volume":"16","author":"Colston","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1021\/acs.jpcb.5c00953","article-title":"The Impact of Permeation Enhancers on Transcellular Permeation of Small Molecule Drugs","volume":"129","author":"Bernaldez","year":"2025","journal-title":"J. Phys. Chem. B"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"122131","DOI":"10.1016\/j.ijpharm.2022.122131","article-title":"Characterization of the Physicochemical Interactions between Exenatide and Two Intestinal Permeation Enhancers: Sodium Caprate (C10) and Salcaprozate Sodium (SNAC)","volume":"626","author":"Twarog","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/dom.14632","article-title":"Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects with Type 2 Diabetes","volume":"24","author":"Meier","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1021\/acs.molpharmaceut.0c00668","article-title":"Influence of Bile Composition on Membrane Incorporation of Transient Permeability Enhancers","volume":"17","author":"Hossain","year":"2020","journal-title":"Mol. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"19180","DOI":"10.1039\/D3NR05571J","article-title":"Revealing the Interaction between Peptide Drugs and Permeation Enhancers in the Presence of Intestinal Bile Salts","volume":"15","author":"Hossain","year":"2023","journal-title":"Nanoscale"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s40262-021-01025-x","article-title":"Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials","volume":"60","author":"Overgaard","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40262-023-01223-9","article-title":"Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects","volume":"62","author":"Forte","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/dom.14487","article-title":"Recent Developments in GLP-1RA Therapy: A Review of the Latest Evidence of Efficacy and Safety and Differences within the Class","volume":"23","author":"Bain","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1042\/bj3350481","article-title":"Mechanism of Activation of the Gastric Aspartic Proteinases: Pepsinogen, Progastricsin and Prochymosin","volume":"335","author":"Richter","year":"1998","journal-title":"Biochem. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of Oral Semaglutide Compared with Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients with Type 2 Diabetes: A Randomized Clinical Trial","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1111\/dom.15796","article-title":"The Role of Incretin Receptor Agonists in the Treatment of Obesity","volume":"26","author":"Forst","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_29","unstructured":"European Medicines Agency (2020). Rybelsus: Assessment Report, European Medicines Agency."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jconrel.2022.09.034","article-title":"Physical and Barrier Changes in Gastrointestinal Mucus Induced by the Permeation Enhancer Sodium 8-[(2-Hydroxybenzoyl)Amino]Octanoate (SNAC)","volume":"352","author":"Mortensen","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/00498254.2026.2683901","article-title":"Steady-State Pharmacokinetics of Oral Semaglutide Using Semi-Mechanistic Pharmacokinetic Modelling and Population Simulations","volume":"56","author":"Tiwari","year":"2026","journal-title":"Xenobiotica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1016\/j.xphs.2022.10.003","article-title":"Elucidating a Potential Mechanism of Permeability Enhancer Sodium N-[8-(2-Hydroxybenzoyl) Amino] Caprylate in Rats: Evidence of Lymphatic Absorption of Cyanocobalamin Using the Mesenteric Lymph Duct Cannulated Rat","volume":"111","author":"Chiang","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/1567201053586001","article-title":"Oral Delivery of Insulin with the Eligen(\u00ae) Technology: Mechanistic Studies","volume":"2","author":"Malkov","year":"2005","journal-title":"CDD"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"123680","DOI":"10.1016\/j.ijpharm.2023.123680","article-title":"Development and Evaluation of C10 and SNAC Erodible Tablets for Gastric Delivery of a GIP\/GLP1 Peptide in Monkeys","volume":"650","author":"Tran","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/dom.14054","article-title":"Efficacy, Safety and Cardiovascular Outcomes of Once-daily Oral Semaglutide in Patients with Type 2 Diabetes: The PIONEER Programme","volume":"22","author":"Thethi","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.37765\/ajmc.2020.88554","article-title":"Efficacy of Oral Semaglutide: Overview of the PIONEER Clinical Trial Program and Implications for Managed Care","volume":"26","author":"Rodbard","year":"2020","journal-title":"Am. J. Manag. Care"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_38","unstructured":"U.S. Food and Drug Administration (2026). RYBELSUS and OZEMPIC (Semaglutide) Tablets-Highlights of Prescribing Information."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Kim, D.-H., Hwang, S.-K., Yoon, J.-H., Na, D.H., Park, Y.-J., Chae, Y.-J., Chang, J.-E., and Kim, J.-E. (2026). Formulation Engineering of Oral Semaglutide Tablets: Unleashing Gastric Intestinal Permeation with Sodium Caprate. Pharmaceutics, 18.","DOI":"10.3390\/pharmaceutics18060680"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral Semaglutide 50 Mg Taken Once per Day in Adults with Overweight or Obesity (OASIS 1): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","article-title":"Oral Semaglutide at a Dose of 25 Mg in Adults with Overweight or Obesity","volume":"393","author":"Wharton","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_42","unstructured":"U.S. Food and Drug Administration (2026). Wegovy FDA Drug Label."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.clinthera.2011.05.088","article-title":"Pharmacokinetics of Oral Cyanocobalamin Formulated with Sodium N-[8-(2-Hydroxybenzoyl)Amino]Caprylate (SNAC): An Open-Label, Randomized, Single-Dose, Parallel-Group Study in Healthy Male Subjects","volume":"33","author":"Castelli","year":"2011","journal-title":"Clin. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"104163","DOI":"10.1016\/j.xphs.2026.104163","article-title":"Investigating the SNAC-to-Drug Ratio for the Oral Absorption of Cyanocobalamin in Rats","volume":"115","author":"Chiang","year":"2026","journal-title":"J. Pharm. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.xphs.2020.04.016","article-title":"Evaluating the Pharmacokinetics and Systemic Effects of a Permeability Enhancer Sodium N-[8-(2-Hydroxybenzoyl)Amino] Caprylate in Rats","volume":"109","author":"Chiang","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ddr.21832","article-title":"Challenges of Peptide and Protein Drug Delivery by Oral Route: Current Strategies to Improve the Bioavailability","volume":"82","author":"Verma","year":"2021","journal-title":"Drug Dev. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.beha.2004.03.007","article-title":"Oral Delivery of Heparin: SNAC and Related Formulations","volume":"17","author":"Pineo","year":"2004","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1177\/0091270007307242","article-title":"Pharmacokinetics and Pharmacodynamics of Oral Heparin Solid Dosage Form in Healthy Human Subjects","volume":"47","author":"Mousa","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1161\/01.CIR.98.16.1610","article-title":"Oral Delivery of Anticoagulant Doses of Heparin: A Randomized, Double-Blind, Controlled Study in Humans","volume":"98","author":"Baughman","year":"1998","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1161\/01.CIR.101.22.2658","article-title":"Orally Administered Unfractionated Heparin with Carrier Agent Is Therapeutic for Deep Venous Thrombosis","volume":"101","author":"Gonze","year":"2000","journal-title":"Circulation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1046\/j.1538-7836.2003.00340.x","article-title":"Oral Heparin Administration with a Novel Drug Delivery Agent (SNAC) in Healthy Volunteers and Patients Undergoing Elective Total Hip Arthroplasty","volume":"1","author":"Berkowitz","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.2165\/0003495-200868180-00011","article-title":"Ibandronate: A Review of Its Use in the Management of Postmenopausal Osteoporosis","volume":"68","author":"Frampton","year":"2008","journal-title":"Drugs"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1773-2247(11)50084-X","article-title":"Study on the Impact of SNAC (Sodium N-[8-(2-Hydroxybenzoyl) Amino] Caprylate) on the Bioavailability of Ibandronate (IBN) in Postmenopausal Women","volume":"21","author":"McIntyre","year":"2011","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S2213-8587(23)00325-X","article-title":"PCSK9 Inhibition with Orally Administered NNC0385-0434 in Hypercholesterolaemia: A Randomised, Double-Blind, Placebo-Controlled and Active-Controlled Phase 2 Trial","volume":"12","author":"Koren","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"156594","DOI":"10.1016\/j.metabol.2026.156594","article-title":"Amycretin in Obesity: Mechanisms, Clinical Efficacy, and Future Perspectives","volume":"179","author":"Fu","year":"2026","journal-title":"Metabolism"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(26)01247-X","article-title":"Efficacy and Safety of Once-Daily Oral Zenagamtide, a Novel Unimolecular GLP-1 and Amylin Receptor Agonist, in Adults with Type 2 Diabetes: A Multicentre, Randomised, Parallel, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Trial","volume":"408","author":"Mora","year":"2026","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(26)01248-1","article-title":"Efficacy and Safety of Once-Weekly Subcutaneous Zenagamtide, a Novel Unimolecular GLP-1 and Amylin Receptor Agonist, in Type 2 Diabetes: A Multicentre, Randomised, Parallel, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Trial","volume":"408","author":"Mora","year":"2026","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","article-title":"Efficacy and Safety of Once-Daily Oral Semaglutide 25 Mg and 50 Mg Compared with 14 Mg in Adults with Type 2 Diabetes (PIONEER PLUS): A Multicentre, Randomised, Phase 3b Trial","volume":"402","author":"Aroda","year":"2023","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40262-018-0728-4","article-title":"Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes","volume":"58","author":"Granhall","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/nutrit\/nuy026","article-title":"Methods to Assess Vitamin B12 Bioavailability and Technologies to Enhance Its Absorption","volume":"76","author":"Brito","year":"2018","journal-title":"Nutr. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1111\/dom.16618","article-title":"Novel Oral Agents in Anti-Obesity Pharmacotherapy: A Narrative Review","volume":"27","author":"Buch","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"124492","DOI":"10.1016\/j.carbpol.2025.124492","article-title":"Oral Efficacy of Structurally Defined Chondroitin Sulfate Co-Administered with SNAC in Parkinson\u2019s Disease","volume":"371","author":"Guo","year":"2026","journal-title":"Carbohydr. Polym."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"124627","DOI":"10.1016\/j.ijpharm.2024.124627","article-title":"Development of Mucoadhesive 3D-Printed Carbopol\/Eudragit\/SNAC Tablets for the Oral Delivery of Enoxaparin: In Vitro and Ex Vivo Evaluation","volume":"664","author":"Chatzitaki","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jconrel.2024.11.036","article-title":"Salcaprozate-Based Ionic Liquids for GLP-1 Gastric Delivery: A Mechanistic Understanding of in Vivo Performance","volume":"377","author":"Rebollo","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"139463","DOI":"10.1016\/j.jcis.2025.139463","article-title":"Engineered Choline-Salcaprozate Ionic Liquids for Enhanced Non-Invasive Delivery of Macromolecular Antidiabetics","volume":"704","author":"Huang","year":"2026","journal-title":"J. Colloid Interface Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jconrel.2024.11.078","article-title":"Combining SNAC and C10 in Oral Tablet Formulations for Gastric Peptide Delivery: A Preclinical and Clinical Study","volume":"378","author":"Niu","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"103851","DOI":"10.1016\/j.xphs.2025.103851","article-title":"Investigating the Effect of Permeation Enhancers on Oral Absorption of a BCS IV Compound, Ombitasvir, Utilizing Animal Models","volume":"114","author":"Indulkar","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"126257","DOI":"10.1016\/j.ijpharm.2025.126257","article-title":"Direct Compression Peptide Tablets: Insights into the Importance of Permeation Enhancer Processibility and Peptide Stability","volume":"685","author":"Fagan","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"114711","DOI":"10.1016\/j.jconrel.2026.114711","article-title":"Gut Microbiota Perturbation and Systemic Inflammation Are Associated with Salcaprozate Sodium (SNAC)-Enabled Oral Semaglutide Delivery","volume":"392","author":"Ariaee","year":"2026","journal-title":"J. Control. Release"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11095-007-9354-9","article-title":"In Vitro Interactions Between the Oral Absorption Promoter, Sodium Caprate (C10) and S. Typhimurium in Rat Intestinal Ileal Mucosae","volume":"25","author":"Cox","year":"2008","journal-title":"Pharm. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40262-019-00756-2","article-title":"Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects","volume":"58","author":"Borregaard","year":"2019","journal-title":"Clin. Pharmacokinet."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1171\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:12:16Z","timestamp":1789575136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":71,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pharmaceutics18091171"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18091171","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}